



Structured Administration and Supply Arrangement (SASA)

TITLE: **Pharmacist Resupply of Oral Contraceptive Pills**

1. Authority:

Issued by the Chief Executive Officer of Health under Part 6 of the Medicines and Poisons Regulations 2016.

2. Scope:

This authorises Registered Pharmacists working in community pharmacy to supply approved oral contraceptive pills (OCP) in defined circumstances.

3. Criteria:

This SASA authorises the actions specified in the table below:

Practitioner:	Registered Pharmacists who have completed approved training in accordance with Appendix 1.
Practice setting:	Registered pharmacy premises approved by the Pharmacy Registration Board of Western Australia. All regions of WA.
Approved activity:	Supply of Schedule 4 oral contraceptive pills for contraceptive purposes.
Approved medicines:	Hormones listed in Appendix 2 in the form of: <ul style="list-style-type: none">• Combined oral contraceptives, or• Progestogen-only contraceptives
Medical conditions:	Contraception in females aged between 16 and 39 years.

4. **Conditions:**

The supply of approved medicines under this SASA is subject to the conditions that:

- a. The pharmacist has an unconditional general registration with the Australian Health Practitioner Regulation Agency (AHPRA);
- b. The pharmacist has successfully completed training in accordance with Appendix 1, and must maintain competency to provide the service, including any ongoing training;
- c. The supply must adhere to the Pharmacist Resupply of Oral Contraceptive Pills – Western Australian Protocol issued by the Western Australian Department of Health;
- d. Only patients who meet the following criteria are eligible for the approved medicines:
 - i. They must be between the ages of 16 and 39 (inclusive).
 - ii. They must have been prescribed the OCP by a general practitioner or a nurse practitioner within the past two years.
 - iii. They must have been using the same OCP consistently for at least two years.
 - iv. They must have continued taking the OCP without interruption since it was prescribed.
- e. Patients aged between 16 and 17 years can receive a single resupply for up to 4 months.
- f. Patients aged between 18 and 39 years can receive resupply for up to 12 months, as long as the supply does not extend the date of the patient's last OCP review with a prescriber beyond two years;
- g. The OCP provided must contain the same hormones and doses that the patient has been using consistently for the past two years. Alterations to the hormones or doses are not allowed;
- h. The medicines are supplied from a pharmacy registered in Western Australia;
- i. The registered pharmacy must have a room suitable to maintain confidentiality of the consultation, where the consultation conducted by a pharmacist cannot be seen or overheard by a person not involved in the consultation;
- j. Completion of a comprehensive clinical record of treatment and generation of a service summary provided to the patient and/or their primary health provider;
- k. Supply, packaging and labelling of the approved medicines is in accordance with Part 9 of the Medicines and Poisons Regulations 2016;
- l. Record keeping of supply is in accordance with Part 12 of the Medicines and Poisons Regulations 2016; and

m. Details of the supply is transmitted to My Health Record.

5. **Issued by:**

Name:	Dr Andrew Robertson
Position:	Chief Health Officer, Department of Health WA
Date:	24 April 2024

Enquiries to: Medicines and Poisons Regulation Branch Number: 041/1-2024

MPRB@health.wa.gov.au

Date: 24 April 2024

APPENDIX 1

Approved Training

Pharmacists must successfully complete a competency-based training delivered through a higher education institution accredited by the Tertiary Education Quality and Standards Agency or an accredited continuing professional development program, that meets the Australian Pharmacy Council's Standards for Continuing Professional Development Activities.

The training must require participants to demonstrate satisfactory knowledge, understanding and minimum competencies in the following areas:

- a. Discuss important aspects of the female reproductive system and reproductive hormones.
- b. Compare the hormonal and non-hormonal contraceptives available in Australia.
- c. Recognise how to assess medical history, clinical risks, individual preferences, and make appropriate contraceptive advice.
- d. Identify appropriate pathways in the management of hormonal contraceptives resupply, including patient counselling and engagement in opportunistic health screenings.
- e. Requirements for resupply of OCP community pharmacy service.

Pharmacists must complete cultural safety and gender diversity training relevant to their place of practice, reflect on their competency and provide the service in ways that are inclusive, culturally safe, sensitive, and responsive.

APPENDIX 2

Approved Medicines

Brand name examples	Estrogen	Progestogen
Progestogen only contraception		
Slinda		drospirenone 4 mg
Microlut		levonorgestrel 30 mcg
Noriday 28-day		norethisterone 350 mcg
Monophasic combined oral contraception		
Low estrogen dose		
Bella, Brooke, Rosie, Yana, Yaz	ethinylestradiol 20 mcg	drospirenone 3 mg
Femme-Tab 20/100, Lenest 20, Loette, Microgynon 20, Micronelle 20		levonorgestrel 100 mcg
Zoely	estradiol 1.5 mg	nomegestrol 2.5 mg
Standard estrogen dose		
Madeline, Marvelon	ethinylestradiol 30 mcg	desogestrel 150 mcg
Valette		dienogest 2mg
Brooklynn, Isabelle, Petibelle, Rosalee, Yasmin, Yelena		drospirenone 3 mg
Minulet		gestodene 75 mcg
Eleanor 150/30, Evelyn 150/30, Femme-Tab 30/150, Lenest 30, Levlen, Microgynon 30, Micronelle 30, Monofeme, Seasonique		levonorgestrel 150 mcg
Norimin, Brevinor	ethinylestradiol 35 mcg	norethisterone 0.5 mg
Norimin-1, Brevinor-1		norethisterone 1 mg
Multiphasic combined oral contraception		
Logynon, Trifeme, Triquilar, Triphasil	ethinylestradiol 30 mcg/40 mcg/30 mcg	levonorgestrel 50 mcg/75 mcg/125 mcg
Qlaira	estradiol 3 mg/2 mg/2 mg/1 mg	dienogest nil/2 mg/3 mg/nil